ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Targeted photodynamic therapy for MCF-7 breast cancer using antibody-conjugated, green-synthesized gold nanoparticles loaded with hypericin: a proof of concept.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Method for Isolating Hypericin fromMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of breast cancer remains a significant clinical challenge, with limited responsiveness to conventional therapies. Photodynamic therapy, using the natural photosensitizer Hypericin, offers a promising modality, but its efficacy is limited by poor solubility, poor selectivity, and non-specific binding. To address these limitations, we developed a targeted nanoplatform leveraging the biocompatibility of gold nanoparticles and targeting capabilities of a monoclonal antibody. This study aimed to synthesize and characterize a novel nanoplatform comprising eco-friendly, green-synthesized gold nanoparticles, loaded with Hypericin, and conjugated with a monoclonal antibody for the targeted photodynamic therapy for MCF-7 breast cancer cells. Gold nanoparticles were synthesized using a green-chemistry approach with an aqueous extract of Kniphophia porphyrantha. Hypericin was loaded onto the nanoparticle surface, followed by the monoclonal antibody attachment to create the bionanoconjugate. The conjugate was characterized by UV-Vis spectroscopy, DLS, and TEM. Cellular uptake and phototoxicity of the nanoplatform were evaluated in MCF-7 cells and compared to non-targeted controls using microscopy, MTT and LDH assay, and flow cytometry upon irradiation with 594 nm diode laser. Treatment with free Hypericin resulted in a 50% reduction in cell viability, while the bionanoconjugate displayed pronounced cytotoxic effects with less than 30% of the cell population remaining viable. 70% reduction in ATP levels was observed in cells treated with the bionanoconjugate, in comparison to only 20% in cells treated with free Hypericin. These results demonstrate the enhanced PDT efficacy resulting from nanoparticle-antibody conjugation.
Indexed as
Identifiers
41954724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.